DEVELOPMENT AND CHARACTERIZATION OF SINGLE LAYER AND MATRIX-TYPE TRANSDERMAL ADHESIVES WITH CANNABIS SATIVA L. EXTRACT RICH IN CANNABIDIOL (CBD)

• Grant number: 24/22377-3
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: June 01, 2025
• End date: May 31, 2026
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Principal Investigator: Priscila Gava Mazzola
• Grantee: Lisa Artioli Zink Degelo
• Host Institution: Faculdade de Ciências Farmacêuticas (FCF). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

After decades of prohibition due to political reasons in the second half of the 20th century, Cannabis has gradually regained space for medicinal use in an increasing number of countries. Over the past 20 years, the interest in Cannabis therapeutic potential has increased rapidly, with applications in various conditions, such as chronic pain, depression, anxiety, sleep disorders and neurological diseases, among others. Globally, it is estimated that more than 50 million people live with chronic degenerative diseases, while in Brazil, projections indicate that by 2060, over one-third of the population will be elderly, which directly implies a considerable increase in this type of disease. This context reinforces the urgent need for new effective and comfortable treatments to improve patients' quality of life. Cannabinoids stand out as a promising solution in this scenario, as they show broad therapeutic potential with neuroprotective effects, being able to reduce oxidative stress, prevent neuronal death, and decrease the inflammatory process in the central nervous system. However, in Brazil, cannabinoids-based medications can only be register and commercialized for oral use, a route that presents very low bioavailability. Therefore, studying alternatives routes of administration is essential to higher patients' quality of life and expand therapeutic options. For chronic diseases, the transdermal route is a promising option, as it allows controlled release of the active ingredient, reducing the dosage and frequency of administration. This project continues the "Development of transdermal formulations with medicinal Cannabis", focusing on creating a transdermal patch to carry cannabinoids and ensure the permeation of these compounds as an alternative for medicinal Cannabis administration. (AU)